Volume 17, Number 9—September 2011
Research
Estimating Effect of Antiviral Drug Use during Pandemic (H1N1) 2009 Outbreak, United States
Table 6
% Prescriptions written for prophylaxis | % Prescriptions resulting in nonadherence + stockpiling | Net no. prescriptions used to treat clinically diagnosed influenza | Median no. hospitalizations averted, by patient age group, y† |
|||
---|---|---|---|---|---|---|
0–17 | 18–64 | >65 | Total | |||
0 | 0 | 8,177,542 | 3,839 | 10,837 | 3,383 | 18,059 |
10 | 10 | 6,542,034 | 3,071 | 8,669 | 2,707 | 14,447 |
>10 | >20 | 5,724,279 | 2,687 | 7,586 | 2,368 | 12,641 |
20 | 20 | 4,906,525 | 2,303 | 6,502 | 2,030 | 10,835 |
20 | 30 | 4,088,771 | 1,920 | 5,418 | 1,692 | 9,030 |
30 | 30 | 3,271,017 | 1,536 | 4,335 | 1,353 | 7,224 |
*Baseline data used displays 10% for prophylaxis and 20% for personal stockpiling and non-adherence. This baseline assumption was used to generate results in Table 5.
†Results of sensitivity analysis were calculated by using the upper median estimates of antiviral effectiveness in preventing hospitalization among the clinically ill (Table 1, Table 2).
Page created: June 19, 2012
Page updated: June 19, 2012
Page reviewed: June 19, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.